ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 191 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2018. The put-call ratio across all filers is 1.26 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,481,000 | +7.9% | 52,800 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,373,000 | -31.5% | 52,800 | -2.0% | 0.00% | -50.0% |
| Q3 2020 | $2,003,000 | -31.8% | 53,900 | -5.8% | 0.00% | -33.3% |
| Q2 2020 | $2,936,000 | +65.0% | 57,215 | +1.4% | 0.00% | +50.0% |
| Q1 2020 | $1,779,000 | -47.4% | 56,415 | -0.5% | 0.00% | -33.3% |
| Q4 2019 | $3,382,000 | +100.0% | 56,715 | +23.0% | 0.00% | +50.0% |
| Q3 2019 | $1,691,000 | +13.4% | 46,113 | +43.9% | 0.00% | 0.0% |
| Q2 2019 | $1,491,000 | +36.5% | 32,047 | +17.8% | 0.00% | +100.0% |
| Q1 2019 | $1,092,000 | -14.9% | 27,200 | -2.5% | 0.00% | -50.0% |
| Q4 2018 | $1,283,000 | -1.3% | 27,900 | -4.8% | 0.00% | 0.0% |
| Q3 2018 | $1,300,000 | -3.8% | 29,300 | -15.0% | 0.00% | 0.0% |
| Q2 2018 | $1,351,000 | -58.6% | 34,478 | -23.5% | 0.00% | -60.0% |
| Q1 2018 | $3,262,000 | +1.4% | 45,092 | -7.7% | 0.01% | +25.0% |
| Q4 2017 | $3,217,000 | +33.3% | 48,858 | +1.5% | 0.00% | 0.0% |
| Q3 2017 | $2,414,000 | +24.5% | 48,158 | +14.9% | 0.00% | +33.3% |
| Q2 2017 | $1,939,000 | +31.1% | 41,900 | 0.0% | 0.00% | +50.0% |
| Q1 2017 | $1,479,000 | +169.9% | 41,900 | -4.3% | 0.00% | +100.0% |
| Q4 2016 | $548,000 | -14.0% | 43,800 | -4.8% | 0.00% | 0.0% |
| Q3 2016 | $637,000 | +30.8% | 46,000 | -6.7% | 0.00% | 0.0% |
| Q2 2016 | $487,000 | -43.4% | 49,300 | -3.1% | 0.00% | 0.0% |
| Q1 2016 | $861,000 | -28.4% | 50,900 | -5.7% | 0.00% | -50.0% |
| Q4 2015 | $1,202,000 | -20.5% | 54,000 | -15.8% | 0.00% | -33.3% |
| Q3 2015 | $1,512,000 | -71.2% | 64,100 | 0.0% | 0.00% | -62.5% |
| Q2 2015 | $5,241,000 | +231.5% | 64,100 | +91.1% | 0.01% | +300.0% |
| Q1 2015 | $1,581,000 | 0.0% | 33,547 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,581,000 | +129.1% | 33,547 | +18.9% | 0.00% | +100.0% |
| Q3 2014 | $690,000 | +80.6% | 28,216 | +17.1% | 0.00% | 0.0% |
| Q2 2014 | $382,000 | – | 24,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $27,840,842 | 18.82% |
| Ikarian Capital, LLC | 1,891,147 | $11,781,846 | 2.84% |
| Altium Capital Management LP | 620,000 | $3,862,600 | 1.96% |
| Ikarian Capital, LLC | 1,296,900 | $8,079,687 | 1.95% |
| Parkman Healthcare Partners LLC | 822,784 | $5,125,944 | 1.36% |
| Deep Track Capital, LP | 4,000,000 | $24,920,000 | 1.05% |
| Monaco Asset Management SAM | 470,100 | $2,928,723 | 0.88% |
| BRAIDWELL LP | 3,393,405 | $21,140,913 | 0.71% |
| Telemetry Investments, L.L.C. | 71,000 | $442 | 0.70% |
| Rhenman & Partners Asset Management AB | 900,000 | $5,607,000 | 0.58% |